PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and ...

As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs. 14 placebo deaths, HR=0.301, p=0.0143) CNM-Au8 treatment was ...

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...